Clubul Sanatatii S.R.L.
- Address
- lock Available on a paid plan
Immune System Diseases
The neurology department at Clubul Sanatatii S.R.L. conducts studies that target immune‑driven neurological conditions, aiming to confirm the safety and therapeutic benefit of novel immunomodulators.
- Long‑term safety assessment of ocrelizumab in adults with multiple sclerosis
- Comparative efficacy of remibrutinib versus teriflunomide for reducing relapse frequency
- Evaluation of frexalimab on annualized relapse rates in relapsing forms of multiple sclerosis
- Investigation of IMU‑838 versus placebo in delaying first relapse in relapsing multiple sclerosis
Across nine active trials and seven investigators, the site focuses on improving disease control and quality of life for patients with immune‑mediated nervous system disorders.
Musculoskeletal Diseases
Research at the clinic also addresses peripheral nerve disorders that affect muscular function, with the goal of enhancing patients’ daily capabilities.
- Efficacy and safety of empasiprubart IV for functional improvement in Chronic inflammatory demyelinating polyneuropathy
Although fewer in number, these studies complement the broader neurological program by targeting neuromuscular health in the Campulung community.
Nervous System Diseases
The primary research focus is on central nervous system disorders, especially various forms of multiple sclerosis and migraine, seeking to reduce disability progression and prevent attacks.
- Preventive potential of Lu AG09222 for patients with refractory migraine
- Impact of SAR442168 on disability delay in primary progressive multiple sclerosis
- Effectiveness of remibrutinib in secondary progressive multiple sclerosis
- Comprehensive evaluation of ocrelizumab versus placebo on MRI‑defined disease activity
With a portfolio of nine clinical trials, the site strives to bring innovative therapies to individuals living with chronic nervous system diseases throughout Romania.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Novartis Pharma AG1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clubul Sanatatii S.R.L.
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 3 | Unknown | 2019-09-19 | 2024-01-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.